



Industry Genomics Network Alliance

Prospectus 2026

INDUSTRY COLLABORATION FOR AUSTRALIA'S GENOMICS FUTURE

Prospectus Overview

- Strategic overview of InGeNA
- Advocacy & Impact
- Why now matters
- Current priorities and activities
- Benefits for members
- Contact us

Australia's united industry voice for the future of genomics

Making personalised healthcare accessible to all Australians by harnessing the collective skills and expertise of industry to accelerate the adoption of genomics and precision medicine

Influence

Advocate for policy changes to drive genomics & precision medicine adoption and access

Delivery

Contribute to the advancement of personalised healthcare through the promotion of genomics

Innovation

Facilitate industry's role in helping create the healthcare system of tomorrow

+113%
Membership growth

+75%
Income growth

+23%
Growth in
Partnerships

11
Submissions to
Federal & State Policy

7
Presentations at
global conferences

1
Major industry
award win

40
Member meetings

8
InGeNA-hosted
networking events

25
Newsletters
sent

+52%
Social media
engagement

+1,134%
Increase in website
downloads

+430%
Website engagement

3
Official media
releases

6
Mentions or interviews
in industry media

87
Owned news
items published

Performance Metrics 24-25

InGeNA established itself as Australia's trusted peak industry body for genomics and precision medicine.

- Membership growth: +113%
- Income growth: +75%

Strong engagement with government:

- regular policy submissions, including invited ministerial contributions
- ongoing participation in key national policy processes

Growing industry alignment:

- expanded membership across pharma, diagnostics, and system enablers
- coordinated, unified voice to government

Current InGeNA Members & Partners



Associate Members



Partners



Because of InGeNA:

- Industry has a **direct and ongoing role** in Genomics Australia policy structures
- Comprehensive Genomic Profiling has shifted from concept to **policy-ready implementation pathway**
- A National Genomic Test Directory is **under active policy consideration**
- Government recognises the need for **HTA reform for genomics platforms**
- Focused Parliamentary Friends Group on Genomics and Genetic Testing
- Fragmented industry advocacy has been replaced with **coordinated, system-level influence**

These shifts directly shape the conditions for market access, adoption and scale.

How Members Benefit

Strong industry body – formed by industry for industry

- **Advocacy & Impact** – Gain a seat at the table to shape government priorities and consultations.
- **Policy Leadership** – Join our Policy Working Group and help define industry positions.
- **Stay Informed** – Access exclusive insights and key decisions.
- **Stronger Together** – Collaborate with industry and consumer leaders to navigate complexities.
- **Targeted Support** – Benefit from individual and collective initiatives.
- **Agile & Impactful** – A united, responsive industry voice.

How InGeNA helps Global Pharma

- De-risk market access for genomics-enabled medicines
- Improve predictability of reimbursement and funding signals
- Strengthen clinical trial ecosystem readiness
- Align policy settings to future pipeline needs

Partnering to Scale Genomics-Enabled Oncology in Australia

- Supporting access to biomarker-driven therapies through system readiness, policy reform and implementation
- **Why This Matters Now**
 - Australia is entering a decisive implementation phase for genomics.
 - National policy and infrastructure settings are being defined (2026–2028)
 - Genomics Australia and the National Framework are moving into implementation
 - States are actively seeking guidance from industry on how to scale genomics in practice

InGeNA's 2026 Strategic Focus: Turning Policy into Patient Access

- InGeNA is focused on four system levers that determine access, adoption and scale:
 - Testing & Access Infrastructure
 - Data & System Readiness
 - HTA & Market Access Reform
 - Clinical & Trial Ecosystem
- These levers address the full pathway from biomarker identification through to treatment access and system adoption.
- Programs are co-designed with members through our Working Groups

Advocacy and Industry representation

Focused advocacy providing a united voice for the genomics industry, and serving as a trusted advisor and conduit between industry and government.



HTA MSAC systemic Reform focus



Ongoing seat at the table on Genomics Australia Advisory Council as sole industry voice



Therapeutic recommendation reporting of precision oncology on NGS reports



Roundtables on Genomics & Precision medicine scaling and data



International Keynote visit to influence system priorities



Key conduit between Industry and Govt

Member connectivity and communications

Communications and marketing to position genomics, our members, and the organisation as leaders in the field and create industry alignment.



Regular networking & member meetings



Partnerships to strengthen our advocacy and policy alignment



Targeted campaigns to promote genomics & member achievements.



Dedicated member communications to share updates

Recent Submissions

- **Advocacy & Consultation** – Representing members
 - Cancer Australia National Framework on Genomics in Cancer Control
 - Rare Cancers Australia
 - Genomics Australia EAG
 - National Health Genomics Policy Framework
 - Genetic Insurance Discrimination
 - MRFF Genetic Health Future's Mission
 - R&D Discussion, DISR
- View our Submission page ([Link here](#))



What InGeNA membership looks like for you

- Input into policy positions that affect biomarker testing and reimbursement
- Participation in closed-door briefings with government
- Ability to shape genomic and precision medicine, including CGP implementation pathways
- Early visibility of:
 - funding signals
 - system design decisions
 - infrastructure investments
- Alignment with clinicians and consumers → reduces advocacy risk

Membership – Tiered levels aligned to AU Revenue

Company size (Australian revenue)	Annual membership fee	Notes
Start-up (\$0–5M)	\$500 (Year 1)	\$750 (Year 2), \$1,000 (Year 3), then Band 1
Small business (<\$10M)	\$1,500	
Band 1 (\$10M–\$75M)	\$5,000	10% discount for Australian-owned
Band 2 (\$75M–\$150M)	\$10,000	10% discount for Australian-owned
Band 3 (\$150M–\$250M)	\$15,000	10% discount for Australian-owned
Band 4 (\$250M–\$500M)	\$20,000	10% discount for Australian-owned
Band 5 (>\$500M)	\$25,000	10% discount for Australian-owned

A 10% discount applies for an upfront three-year membership commitment (invoiced annually).

Member Testimonials from our Pharma Partners

“InGeNA is the only organisation convening leaders across medical, pathology and digital health to align priorities and deliver practical solutions for precision medicine implementation in Australia. Its strength lies in coordinated, strategic advocacy that drives the ecosystem change needed to reshape the health system. InGeNA provides the leadership and focus required to implement precision medicine in Australia.”

“InGeNA creates a collaborative environment where challenges across the full scope of precision medicine can be shared. This fosters a broader understanding of integration issues and aligns policy positions, making industry advocacy more efficient. When the precision medicine industry speaks with a unified voice, the Government listens; InGeNA is uniquely placed, through its broad membership, to make this happen.”

“Being part of InGeNA provides us with numerous benefits such as amplifying the voice of the genomics industry in a consolidated and united manner to help shape policy and improve healthcare outcomes in Australia. We receive the latest industry news, hear from leading experts in various areas within genomics and collectively work on projects which will educate and inform government and the broader genomics healthcare industry.”

Other benefits of membership:

- Ability to collectively advocate for genomics adoption to government and policy makers
- Support for MSAC submissions and influencing positive policy change in genomics
- Keeping up to date with the latest developments in the genomics industry
- Networking and establishing our organisation as a valued partner in genomics
- Access to industry webinars and events

Member Testimonials cont'd

“One of the great things about InGeNA is the personal way we get to interact, especially when responding to policy submissions, which are so important in shaping government understanding of industry needs. InGeNA brings the whole industry together for meaningful discussions, like the policy roundtable they hosted. InGeNA is the only forum where we can come together and really think deeply about the challenging issues that matter most.”

Dr Natalie Thorne - CSO, Genomical

“InGeNA enables TrakGene to collaborate, create a united voice, align viewpoints and position industry in the evolving conversation and initiatives for the Australian community, helping our organisations grow.

Genomics is seen a core focus for the future of healthcare by the Australian Government, and InGeNA provides a centralised reference point to engage with industry stakeholders, enabling structured and succinct response to initiatives and understanding of future opportunities.”

Andrew Grant, CEO, TrakGene

"InGeNA membership helps us to keep up to date with initiatives and announcements about genomics from state & federal governments affecting the clinical and industry space, which is really useful in this highly dynamic area. It's important for us to be aware of what's going on, but it can be difficult for us to keep track of the number of announcements, so having InGeNA monitoring and sharing with members is really useful."

Mark Crowe - National Research Partnerships Manager, AGRF

Engage in 2026

- 2026 is an implementation year.
- Organisations engaging now will help shape:
 - National genomic infrastructure settings
 - Funding and reimbursement pathways
 - Precision medicine trial readiness
 - CGP mainstreaming
- We welcome structured conversations to align engagement to your Australian strategy
- To explore Membership or Strategic Partnership options:

Contact Dr Erin Evans
CEO, InGeNA
ceo@ingena.org.au
+61 448 848 016

Contact us to find out more



Contact: Erin Evans, CEO



+61 448848016 or 07 5407 0452



info@ingena.org.au



Visit our website for the latest updates, events,
and membership opportunities:

<https://ingena.org.au>



Sign up to our newsletter [here](#)





Thank you

Dr Erin Evans, CEO

E ceo@ingena.org.au

M +61 448 848 016